ArticleBritish journal of cancer2013
Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Diagnostic and prognostic significance of ALU-based cell-free DNA in colorectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.Scientific reports · 2017Pooled it
- The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis.International journal of clinical oncology · 2017Pooled it
- LINE-1 methylation levels, a biomarker of weight loss in obese subjects, are influenced by dietary antioxidant capacity.Redox report : communications in free radical research · 2016Trial
- LINE-1 retrotransposons: Multifaceted functions and regulatory mechanisms in health and disease.Molecular therapy. Nucleic acids · 2026Review
- Unraveling LINE-1 retrotransposition in head and neck squamous cell carcinoma.Molecular oncology · 2025Article
- Pan-cancer analysis reveals context-dependent roles of LINE-1 ORF1p in immune regulation and copy number alterations.bioRxiv : the preprint server for biology · 2025Article
- Histone modifications in cervical cancer: Epigenetic mechanisms, functions and clinical implications (Review).Oncology reports · 2025Review
- LINE-1 methylation status and survival outcomes in colorectal cancer patients: A systematic review and meta-analysis.Heliyon · 2025Article
- H3K27me3 Immunohistochemical Loss Predicts Lower Response to Neo-Adjuvant Chemo-Radiotherapy in Rectal Carcinoma.Biomedicines · 2022Article
- SIRT6 Through the Brain Evolution, Development, and Aging.Frontiers in aging neuroscience · 2021Article
- Impact of LINE-1 hypomethylation on the clinicopathological and molecular features of colorectal cancer patients.PloS one · 2018Article
- Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers.Annals of translational medicine · 2017Review
- Chronic exposure to arsenic, LINE-1 hypomethylation, and blood pressure: a cross-sectional study in Bangladesh.Environmental health : a global access science source · 2017Article
- LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.Oncotarget · 2017Article
- Abnormal expression of mRNA, microRNA alteration and aberrant DNA methylation patterns in rectal adenocarcinoma.PloS one · 2017Article
- Targeting histone methylation for colorectal cancer.Therapeutic advances in gastroenterology · 2017Review
- Tumor LINE-1 Methylation Level in Association with Survival of Patients with Stage II Colon Cancer.International journal of molecular sciences · 2016Article
- Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.Oncotarget · 2016Article
- Filtered selection coupled with support vector machines generate a functionally relevant prediction model for colorectal cancer.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundWe evaluated the clinical prognostic value of methylation of two non-coding repeat sequences, long interspersed element 1 (LINE-1) and Alu, in rectal tumour tissues. In addition to DNA methylation, expression of histone modifications H3K27me3 and H3K9Ac was studied in this patient cohort.
methodsLINE-1 and Alu methylation were assessed in DNA extracted from formalin-fixed paraffin-embedded tissues. A pilot (30 tumour and 25 normal tissues) and validation study (189 tumour and 53 normal tissues) were performed. Histone modifications H3K27me3 and H3K9Ac were immunohistochemically stained on tissue microarrays of the study cohort.
resultsIn early-stage rectal cancer (stage I-II), hypomethylation of LINE-1 was an independent clinical prognostic factor, showing shorter patient survival (P=0.014; HR: 4.6) and a higher chance of tumour recurrence (P=0.001; HR: 9.6). Alu methylation did not show any significant correlation with clinical parameters, suggesting an active role of LINE-1 in tumour development. Expression of H3K27me3 (silencing gene expression) and H3K9Ac (activating gene expression) in relation to methylation status of LINE-1 and Alu supported this specific role of LINE-1 methylation.
conclusionThe epigenetic status of LINE-1, but not of Alu, is prognostic in rectal cancer, indicating an active role for LINE-1 in determining clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.